Nanomedicines consisting of nanoparticles for targeted drug delivery to specific tissues and cells offer new solutions for cancer diagnosis and therapy. In a recent study, researchers systematically evaluated the size-dependent biological profiles of three monodisperse drug-silica nanoconjugates to determine the optimum particle size for tissue penetration and tumor inhibition.

Source: Optimal particle size for anticancer nanomedicines discovered


David Cottle

UBB Owner & Administrator